Healthcare Services

Central Nervous System Biomarkers Market Revenue Growth Expected to Reach $9.92 Billion by 2030 with 10.2% CAGR

March 31, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Central Nervous System Biomarkers Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The central nervous system biomarkers market has experienced substantial growth in its size over recent years. It is projected to expand from $6.14 billion in 2025 to $6.74 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.8%. The growth observed in the historic period can be ascribed to the increasing prevalence of neurological disorders, advancements in neuroimaging and assay technologies, growing clinical research activity in neurology, rising demand for disease progression monitoring, and the expansion of biomarker validation studies.

The central nervous system biomarkers market is anticipated to show significant expansion over the next few years, projected to reach $9.92 billion by 2030, reflecting a compound annual growth rate (CAGR) of 10.2%. This growth throughout the forecast period is attributed to factors such as increased investments in precision neurology, the growing application of biomarkers in personalized medicine, the rising adoption of AI-driven biomarker discovery, the expansion of biomarker-guided clinical trials, and enhanced regulatory acceptance of biomarker endpoints. Prominent trends expected during this period involve the increasing uptake of blood-based CNS biomarkers, the growing deployment of biomarkers in drug development pipelines, a heightened focus on early detection of neurodegenerative diseases, the proliferation of companion diagnostic biomarkers, and improved integration of multi-omics data.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12632&type=smp

What Key Drivers Are Influencing The Growth Of The Central Nervous System Biomarkers Market?

An increase in neurological disorders is projected to propel the expansion of the central nervous system biomarker market. Neurological disorders refer to diverse conditions that affect the brain, spinal cord, and nerves across the body, arising from various factors including genetic predispositions, infections, autoimmune responses, degenerative processes, tumors, vascular problems, and traumatic injuries. Within these conditions, central nervous system (CNS) biomarkers are instrumental in clinical diagnosis, evaluating illness risk or prognosis, determining the disease stage, and monitoring treatment response. Their role is significant in understanding and treating these diseases. For instance, in April 2023, the Centers for Disease Control and Prevention, a US-based government agency, reported that an estimated 6.7 million Americans aged 65 and older were affected by Alzheimer’s disease. This figure is anticipated to nearly triple to 14 million by 2060, with the number of individuals living with the disease doubling every five years after the age of 65. Therefore, the growing prevalence of neurological illnesses is a primary driver for the central nervous system biomarker market’s growth.

What Major Segment Divisions Exist Within The Central Nervous System Biomarkers Market?

The central nervous system biomarkers market covered in this report is segmented –

1) By Type: Safety Biomarker, Efficacy Biomarker, Validation Biomarker, Other Types

2) By Disease: Multiple Sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Traumatic Brain Injury, Other Diseases

3) By Application: Drug Discovery And Development, Personalized Medicines, Disease Risk Assessment, Diagnostics, Other Applications

4) By End-Users: Diagnostic Labs, Clinics, Hospitals, Research Centers, Other End-Users

Subsegments:

1) By Safety Biomarker: Toxicity Biomarkers, Adverse Event Biomarkers

2) By Efficacy Biomarker: Pharmacodynamic Biomarkers, Response Biomarkers

3) By Validation Biomarker: Predictive Biomarkers, Prognostic Biomarkers

4) By Other Types: Diagnostic Biomarkers, Biomarkers For Disease Progression

How Are Trends Transforming The Central Nervous System Biomarkers Market Landscape?

Leading firms within the central nervous system biomarker market are concentrating on bringing advanced solutions, like assay kits, to market. An assay kit consists of a pre-assembled collection of reagents and materials utilized for carrying out a particular scientific analysis. For example, in June 2023, Sysmex Corporation, a research and development company based in Japan, introduced an Automated Immunoassay System. This assay kit is engineered to detect the buildup of amyloid beta (Aβ) in the brain, a known contributor to Alzheimer’s disease, by analyzing a minimal blood sample. It quantifies the proportion of Aβ peptides present in the blood, employing an automated immunoassay system. This enables clinicians to pinpoint Aβ accumulation in the brain through a small blood sample, facilitating earlier diagnosis and subsequent treatment for individuals.

Which Companies Are Leading Innovation In The Central Nervous System Biomarkers Market?

Major companies operating in the central nervous system biomarkers market are F. Hoffmann-La Roche AG, Novartis AG, Siemens Healthineers, Thermo Fisher Scientific Inc, Abbott Laboratories, Merck KGaA, Eurofins Scientific, Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Axon Neuroscience SE, Alector Inc., Oryzon Genomics S.A., Banyan Biomarkers Inc., Anavex Life Sciences Corp., Applied Neurosolutions Inc., C2N Diagnostics, Alzheon Inc., DiaGenic ASA, Avid Radiopharmaceuticals Inc., Cassava Sciences Inc.

Read the full central nervous system biomarkers market report here:

https://www.thebusinessresearchcompany.com/report/central-nervous-system-biomarkers-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Central Nervous System Biomarkers Market?

North America was the largest region in the central nervous system biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Central Nervous System Biomarkers Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12632&type=smp

Browse Through More Reports Similar to the Global Central Nervous System Biomarkers Market 2026, By The Business Research Company

Non Hodgkin Lymphoma Nhl Global Market Report

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Non Hodgkin Lymphoma Nhl Global Market Report

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Non Hodgkin Lymphoma Nhl Global Market Report

https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795